Evaxion A/S (NASDAQ: EVAX) will present data demonstrating its AI-Immunology platform's ability to design vaccines for glioblastoma at the American Association for Cancer Research Annual Meeting on April 22, 2026.

The Copenhagen-based clinical-stage company collaborated with researchers at Duke University School of Medicine to identify endogenous retrovirus-derived antigens in tumor samples from glioblastoma patients. The research aimed to develop vaccines for the brain cancer, which has limited therapeutic options.

The study analyzed ERV expression in patient tumor samples and assessed vaccine design feasibility. Experimental data showed immunologic responses to the discovered ERV antigens. The analysis also identified neoantigens suitable for vaccine inclusion in most patients.

"There is a dire need for better treatment options for glioblastoma, which is refractory to immunotherapy due to low mutational burden and paucity of canonical neoantigens," said Professor Mustafa Khasraw from Duke University School of Medicine. "We are encouraged to have found a new tumor-specific antigen source in ERVs that can be targeted by vaccines alongside mutation-derived epitopes."

ERVs are tumor antigens present in tumors but absent in normal tissue. Glioblastoma patients typically have few neoantigens to target due to low mutational burden, according to the company.

The data will be presented as a poster titled "Endogenous retrovirus-derived neoantigens enable a personalized cancer vaccine strategy for glioblastoma" during the meeting in San Diego, California. Megan Benz from Duke University Medical Center will present the findings.

Evaxion's AI-Immunology platform uses artificial intelligence to develop vaccine candidates for cancer and infectious diseases. The company has developed a pipeline of personalized and off-the-shelf cancer vaccine candidates.